• MitMAB for Organoid Endocytosis Studies

  2026-08-18

  MitMAB enables a controlled test of whether dynamin-dependent membrane scission contributes to extracellular-vesicle uptake in polarized intestinal models. This workflow connects polarity-resolved organoids with practical dose screening, trafficking readouts, and troubleshooting for more interpretable intracellular trafficking research.

• Clodronate Liposomes for Causal TAM Studies

  2026-08-18

  Clodronate Liposomes can turn macrophage abundance from a descriptive biomarker into a testable variable in colorectal cancer immunotherapy research. This article explains how to pair liposome-mediated depletion with the CCL7–TAM–CD8+ T-cell axis to improve causal interpretation, controls, and assay design.

• Bromodomain Inhibitor, (+)-JQ1: Research Workflows

  2026-08-17

  Bromodomain Inhibitor, (+)-JQ1 enables controlled BET and BRD4 perturbation across cancer, apoptosis, inflammatory, and reproductive biology models. Its strongest workflow advantage emerges when paired with orthogonal readouts, including EMT assays, caspase 3/7 activity, cytokine profiling, and BRDT-dependent spermatogenesis studies.

• Capecitabine in Patient-Matched Gastric Assembloids

  2026-08-17

  Capecitabine provides a mechanistically informative way to test enzyme-dependent fluoropyrimidine activation in tumor-only and patient-matched tumor–stroma models. This workflow shows how to compare response heterogeneity, validate activation biology, and troubleshoot assays without mistaking stromal protection for intrinsic drug resistance.

• Bedaquiline: An Assay-First View of TB and Cancer

  2026-08-16

  Bedaquiline is more than a diarylquinoline antibiotic: its bioenergetic mechanism creates distinct assay opportunities in tuberculosis and cancer metabolism. This evidence-led guide shows how to separate direct bacterial killing, host-directed effects, and mitochondrial stress without overinterpreting cross-domain findings.

• Bifendate (DDB): A Causal Assay Framework

  2026-08-15

  Bifendate (DDB) is a research tool for investigating hepatoprotection, lipid metabolism, and autophagy. This guide develops a causal assay framework that connects lipid phenotypes with pathway-level readouts while separating evidence for DDB from findings reported for berberrubine.

• Troglitazone Workflows for Reliable Cell Assays

  2026-08-14

  Learn how Troglitazone, SKU A3893, can support better-controlled viability, proliferation, and cytotoxicity experiments through defined solubility, storage, and mechanism-aware assay design. The article connects PPARγ biology with renal carcinoma and tumor-associated macrophage research while separating established evidence from practical workflow recommendations.

• ABT-737 BCL-2 Protein Inhibitor Workflow

  2026-08-14

  ABT-737 is a BH3 mimetic BCL-2 protein inhibitor for mapping mitochondrial apoptosis, comparing cancer-cell dependencies, and testing mechanism-focused combinations. This guide translates its target profile into practical cell-based workflows, reference-informed readouts, and troubleshooting decisions for lymphoma, multiple myeloma, SCLC, and AML research.

• Praeruptorin A: Ferroptosis Workflow Guide

  2026-08-13

  Praeruptorin A connects DMT1-mediated iron overload with ferroptosis, offering a mechanism-led workflow for doxorubicin cardiomyopathy research. The same angular pyranocoumarin compound can be adapted to intestinal barrier, inflammation, and tumor-invasion assays when concentration, timing, and orthogonal readouts are carefully controlled.

• RNF114, PARP1 Trapping, and BRCA Synthetic Lethality

  2026-08-13

  Li et al. identified RNF114 as a PARylation-dependent E3 ubiquitin ligase that regulates PARP1 removal from DNA lesions. Their work shows that nimbolide inhibits this pathway, intensifies PARP1 trapping, selectively kills BRCA-mutated cancer cells, and can overcome both intrinsic and acquired resistance to PARP inhibitors.

• Rucaparib: From PARP Biology to Assay Design

  2026-08-12

  Rucaparib (AG-014699) is a powerful PARP1 research tool for connecting DNA repair, radiosensitization, and cancer-cell state. This guide translates spliceosome findings in hepatocellular carcinoma into biomarker-aware assay design without overstating clinical evidence.

• Dabigatran etexilate: Direct Thrombin Assay Guide

  2026-08-12

  Build more reproducible thrombin, plasma-clotting, and platelet workflows with Dabigatran etexilate, while accounting for its prodrug chemistry and limited water solubility. This guide connects nanomolar potency data with practical stock preparation, assay selection, troubleshooting, and translational anticoagulant research.

• Praeruptorin A Workflows for Inflammation Research

  2026-08-11

  Praeruptorin A is an angular pyranocoumarin compound suited to mechanism-led studies of ferroptosis, epithelial barrier injury, cardiomyopathy, and tumor invasion. This practical guide connects concentration selection, pathway readouts, dosing logistics, and troubleshooting to help researchers build reproducible preclinical workflows.

• Single-Molecule Screening of Fast-Dissociating Antibodies

  2026-08-11

  Miyoshi and colleagues developed a semi-automated single-molecule TIRF microscopy assay that identifies specific antibodies with rapid dissociation directly from hybridoma cultures. The resulting Fab probes supported multiplexed super-resolution imaging and revealed rapid espin turnover within the dense, long-lived actin cores of inner-ear stereocilia.

• Dacarbazine Workflows for Cancer Drug Response

  2026-08-10

  Build more informative Dacarbazine assays by separating growth inhibition from actual cell killing. This workflow combines DNA-damage profiling, endpoint-specific controls, and practical troubleshooting for malignant melanoma, Hodgkin lymphoma, and sarcoma models.

15206 records 1/1014 page Next 12345 下5页 Last page